Beta2-Agonists: Friend or Foe?

Jean G. Ford; Javed Iqbal; Yisa Sunmonu

doi:10.1055/s-2002-34332

Seminars in Respiratory and Critical Care Medicine, Inhaltsverzeichnis

Semin Respir Crit Care Med 2002; 23(4): 369-376
DOI: 10.1055/s-2002-34332

Beta2-Agonists: Friend or Foe?

Jean G. Ford¹ , Javed Iqbal² , Yisa Sunmonu²

¹Bloomberg School of Public Health, Johns Hopkins University, Department of Epidemiology, Baltimore, Maryland
²Division Pulmonary and Critical Care Medicine, Harlem Hospital Center, Columbia University, New York, New York

Abstract

ABSTRACT

This review summarizes the effects of beta2-agonists on asthma severity. There has been a controversy as to whether the regularly scheduled use of beta2-adrenergic agonists increases the risk of adverse outcomes in asthma. A number of epidemiological and clinical studies have found an association between the regularly scheduled use of beta-agonist drugs and increased risk of asthma morbidity and mortality. However, this observation has not been consistent across studies. We discuss here the potential mechanisms to explain the relationship between the use of beta-agonists on a regularly scheduled basis and adverse outcomes of asthma therapy; and we provide a brief review of the effect of genetic diversity at the beta2-adrenergic receptor locus on asthma severity. Overall, the evidence suggests that the beta2-agonists in current use in the United States are generally safe and effective; friends, not foes.

KEYWORDS

Beta2-adrenergic agonists - receptors - asthma - pharmacological - genetics

Volltext

Referenzen

REFERENCES

1 Taylor D R, Sears M R, Cockcroft D W. The beta-agonist controversy. Med Clin North Am . 1996; 80 719-748
2 Mitchell E A. Is current treatment increasing asthma mortality and morbidity?. Thorax . 1989; 44 81-84
3 Sears M R, Taylor D R, Print C G. Regular inhaled β₂-agonist treatment in bronchial asthma. Lancet . 1990; 336 1391-1396
4 Lai C K, Twentyman O P, Holgate S T. The effect of an increase in inhaled allergen dose after rimiterol hydrobromide on the occurrence and magnitude of the late asthmatic response and the associated change in nonspecific bronchial responsiveness. Am Rev Respir Dis . 1989; 140 917-923
5 Swystun V A, Gordon J R, Davis E B, Zhang X, Cockcroft D W. Mast cell tryptase release and asthmatic responses to allergen increase with regular use of salbutamol. J Allergy Clin Immunol . 2000; 106 57-64
6 Cockcroft D W, Bhagat R, Kalra S, Swystun V A. Inhaled beta2-agonists and allergen-induced airway responses. J Allergy Clin Immunol . 1995; 96 1013-1014
7 Bhagat R, Swystun V A, Cockcroft D W. Salbutamol-induced increased airway responsiveness to allergen and reduced protection versus methacholine: dose response. J Allergy Clin Immunol . 1996; 97 47-52
8 Gauvreau G M, Jordana M, Watson R M. Effect of regular inhaled albuterol on allergen-induced late responses and sputum eosinophils in asthmatic subjects. Am J Respir Crit Care Med . 1997; 156 1738-1745
9 Mcivor R A, Pizzichini E, Turner M O. Potential masking effects of salmeterol on airway inflammation in asthma. Am J Respir Crit Care Med . 1998; 158 924-930
10 Matz J, Emmett A, Rickard K, Kalberg C. Addition of salmeterol to low-dose fluticasone versus higher-dose fluticasone:an analysis of asthma exacerbations. J Allergy Clin Immunol . 2001; 107 783-789
11 Kavuru M, Melamed J, Gross G. Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: a randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol . 2000; 105(6 Pt 1) 1108-1116
12 Shapiro G, Lumry W, Wolfe J. Combined salmeterol 50 microg and fluticasone propionate 250 microg in the diskus device for the treatment of asthma.Am J Respir Crit Care Med . 2000; 161(2 Pt 1) 527-534
13 Lazarus S C, Boushey H A, Fahy J V. Long-acting beta2-agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma: a randomized controlled trial. JAMA . 2001; 285 2583-2593
14 Boushey H A, Corry D B, Fahy J V. Asthma. In: Murray JF, Nadel JA, Mason RJ, Boushey HA, eds. Textbook of Respiratory Medicine Philadelphia, PA: WB Saunders 2000: 1248
15 Juniper E F, Frith P A, Hargreave F E. Airways responsiveness to histamine and methacholine: relationship to minimum treatment to control symptoms of asthma. Thorax . 1981; 36 575-579
16 Haahtela T, Jarvinen M, Kava T. Comparison of a beta2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. N Engl J Med . 1991; 325 388-392
17 Taylor D R, Sears M R. Bronchodilators and bronchial hyperresponsiveness. Thorax . 1994; 49 190-191
18 Cockcroft D W, McParland C P, Britto S A, Swystun V A, Rutherford B C. Regular inhaled salbutamol and airway responsiveness to allergen. Lancet . 1993; 342 833-837
19 Peel E T, Gibson G J. Effects of long-term inhaled salbutamol therapy on the provocation of asthma by histamine. Am Rev Respir Dis . 1980; 121 973-978
20 Van Essen-Zandvliet E E, Hughes M D. Effects of 22 months of treatment with inhaled corticosteroids and/or beta-2-agonists on lung function, airway responsiveness, and symptoms in children with asthma. The Dutch Chronic Non-specific Lung Disease Study Group. Am Rev Respir Dis . 1992; 146 547-554
21 van Schayck P C, Graafsma S J, Visch M B, Dompeling E, van Weel C, van Herwaarden L C. Increased bronchial hyperresponsiveness after inhaling salbutamol during 1 year is not caused by subsensitization to salbutamol. J Allergy Clin Immunol . 1990; 86 793-800
22 Wahedna I, Wong C S, Wisniewski A F, Pavord I D, Tattersfield A E. Asthma control during and after cessation of regular beta2-agonist treatment. Am Rev Respir Dis . 1993; 148 707-712
23 Mazzoni L, Naef R, Chapman I D, Morley J. Hyperresponsiveness of the airways following exposure of guinea-pigs to racemic mixtures and distomers of beta2-selective sympathomimetics. Pulm Pharmacol . 1994; 7 367-376
24 Templeton A G, Chapman I D, Chilvers E R, Morley J, Handley D A. Effects of S-salbutamol on human isolated bronchus. Pulm Pharmacol Ther . 1998; 11 1-6
25 Perrin-Fayolle M, Blum P S, Morley J, Grosclaude M, Chambe M T. Differential responses of asthmatic airways to enantiomers of albuterol. Implications for clinical treatment of asthma. Clin Rev Allergy Immunol . 1996; 14 139-147
26 Cockcroft D W, Swystun V A. Effect of single doses of S-salbutamol, R-salbutamol, racemic salbutamol, and placebo on the airway response to methacholine. Thorax . 1997; 52 845-848
27 Walle U K, Pesola G R, Walle T. Stereoselective sulphate conjugation of salbutamol in humans: comparison of hepatic intestinal and platelet activity. Br J Clin Pharmacol . 1993; 35 413-418
28 Mitchell E A. Is current treatment increasing asthma mortality and morbidity?. Thorax . 1989; 44 81-84
29 O'Connor B J, Aikman S L, Barnes P J. Tolerance to the non-bronchodilator effects of inhaled beta2-agonists in asthma. N Engl J Med . 1992; 327 1204-1208
30 Maconochie J G, Minton N A, Chilton J E, Keene O N. Does tachyphylaxis occur to the nonpulmonary effects of salmeterol?. Br J Clin Pharmacol . 1994; 37 199-204
31 Newnham D M, Grove A, McDevitt D G, Lipworth B J. Subsensitivity of bronchodilator and systemic beta2-adrenoceptor responses after regular twice daily treatment with eformoterol dry powder in asthmatic patients. Thorax . 1995; 50 497-504
32 Cheung D, Timmers M C, Zwinderman A H, Bei E H, Dijkman J H, Sterk P J. Long-term effects of a long-acting beta2-adrenoceptor agonist, salmeterol, on airway hyperresponsiveness in patients with mild asthma. N Engl J Med . 1992; 327 1198-1203
33 Lipworth B J, Struthers A D, McDevitt D G. Tachyphylaxis to systemic but not to airway responses during prolonged therapy with high dose inhaled salbutamol in asthmatics. Am Rev Respir Dis . 1989; 140 586-592
34 Nelson H S, Bensch G, Pleskow W W. Improved bronchodilation with levalbuterol compared with racemic albuterol in patients with asthma. J Allergy Clin Immunol . 1998; 102 943-952
35 Taylor D A, Jensen M W, Aikman S L, Harris J G, Barnes P J, O'Connor B J. Comparison of salmeterol and albuterol-induced bronchoprotection against adenosine monophosphate and histamine in mild asthma. Am J Respir Crit Care Med . 1997; 156 1731-1737
36 Chapman K R, Kesten S, Szalai J P. Regular vs as-needed inhaled salbutamol in asthma control. Lancet . 1994; 343 1379-1382
37 Drazen J M, Israel E, Boushey H A, the ACRN. Comparison of regularly scheduled with as-needed use of albuterol in mild asthma. N Engl J Med . 1996; 335 841-847
38 Taylor D R, Town G I, Herbison G P, Boothman-Burrell D, Flannery E M, Hancox B. Asthma control during long-term treatment with regular inhaled salbutamol and salmeterol. Thorax . 1998; 53 744-752
39 Castle W, Fuller R, Hall J, Palmer J. Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment. BMJ . 1993; 306 1034-1037
40 Williams C, Crossland L, Finnerty J. Case-control study of salmeterol and near-fatal attacks of asthma. Thorax . 1998; 53 7-13
41 Pauwels R A, Lofdahl C G, Postma D S. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med . 1997; 337 1405-1411
42 Taylor D R, Sears M R, Herbison G P. Regular inhaled β2-agonist in asthma: effects on exacerbation and lung function. Thorax . 1993; 48 134-138
43 Horwitz R I, Spitzer W, Buist S. Clinical complexity and epidemiologic uncertainty in case-control research: fenoterol and asthma management. Chest . 1991; 100 1586-1591
44 Spitzer W O, Suissa S, Ernst P. The use of beta-agonists and the risk of death and near death from asthma. N Engl J Med . 1992; 326 501-506
45 Blais L, Ernst P, Suissa S. Confounding by indication and channeling over time: the risks of beta2-agonists. Am J Epidemiol . 1996; 144 1161-1169
46 Reishaus E, Innis M, MacIntyre N, Liggett S B. Mutations in the gene encoding for the β₂-adrenergic receptor in normal and asthmatic subjects. Am J Respir Cell Mol Biol . 1993; 8 334-339
47 Green S A, Turki J, Bejarano P, Hall I P, Liggett S B. Influence of β2-adrenergic receptor genotypes on signal transduction in human airway smooth muscle cells. Am J Respir Cell Mol Biol . 1995; 13 25-33
48 Green S A, Turki J, Innis M, Liggett S B. Amino-terminal polymorphisms of the human β₂-adrenergic receptor impart distinct agonist-promoted regulatory properties. Biochemistry . 1994; 33 9414-9419
49 Liggett S B. Polymorphisms of the β2-adrenoceptor and asthma. Am J Respir Crit Care Med . 1997; 156 S156-S166
50 Drysdale C M, McGraw D W, Stack C B. Arnold Complex promoter and coding region beta2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. Proc Natl Acad Sci U S A . 2000; 97 10483-10488
51 Turki J, Pak J, Green S, Martin R, Liggett S B. Genetic polymorphisms of the β₂-adrenergic receptor in nocturnal and non-nocturnal asthma: evidence that Gly 16 correlates with the nocturnal phenotype. J Clin Invest . 1995; 95 1635-1641
52 Martinez F D, Graves P E, Baldini M, Solomon S, Erickson R. Association between genetic polymorphisms of the β2-adrenoceptor and response to albuterol in children with and without a history of wheezing. J Clin Invest . 1997; 100 3184-3188
53 Tan S, Hall I P, Dewar J, Dow E, Lipworth B. Association between β2-adrenoceptor polymorphism and susceptibility to bronchodilator desensitization in moderately severe stable asthmatics. Lancet . 1997; 350 995-999
54 D'amato M, Vitiani L R, Petrelli G. Association of persistent bronchial hyperresponsiveness with beta2-adrenoceptor (ADRB2) haplotypes: a population study. Am J Respir Crit Care Med . 1998; 158 1968-1973
55 Lima J J, Thomason D B, Mohamed M H, Eberle L V, Self T H, Johnson J A. Impact of genetic polymorphisms of the beta2-adrenergic receptor on albuterol bronchodilator pharmacodynamics. Clin Pharmacol Ther . 1999; 65 519-525
56 Holloway J W, Dunbar P R, Riley G A. Association of beta2-adrenergic receptor polymorphisms with severe asthma. Clin Exp Allergy . 2000; 30 1097-1103
57 Summerhill E, Leavitt S A, Gidley H, Parry R, Solway J, Ober C. Beta(2)-adrenergic receptor Arg16/Arg16 genotype is associated with reduced lung function, but not with asthma, in the Hutterites.Am J Respir Crit Care Med . 2000; 162(2 Pt 1) 599-602
58 Kotani Y, Nishimura Y, Maeda H, Yokoyama M. Beta2-adrenergic receptor polymorphisms affect airway responsiveness to salbutamol in asthmatics. J Asthma . 1999; 36 583-590
59 Hancox R J, Sears M R, Taylor D R. Polymorphism of the β₂-adrenoceptor and the response to long-term β2-adrenergic agonist therapy in asthma. Eur Respir J . 1998; 11 589-593
60 Israel E, Drazen J M, Liggett S B. The effect of polymorphisms of the beta(2)-adrenergic receptor on the response to regular use of albuterol in asthma. Am J Respir Crit Care Med . 2000; 162 75-80
61 Hall I P, Wheatly A, Wielding P, Light S B. Association of the Glu 27 ;gY₂-adrenoceptor polymorphism with lower airway reactivity in asthmatic subjects. Lancet . 1995; 345 1213-1214
62 Dewar J C, Wilkinson J, Wheatley A. The glutamine 27 β2-adrenoceptor polymorphism is associated with elevated IgE levels in asthmatic families. J Allergy Clin Immunol . 1997; 100 261-265
63 Dewar J, Wheatley A, Wilkinson J. Association of the Gln 27 β2-adrenoceptor polymorphism and IgE variability in asthmatic families. Chest . 1997; 111 78S-79S
64 Taylor D R, Drazen J M, Herbison G P, Yandava C N, Hancox R J, Town G I. Asthma exacerbations during long term beta-agonist use: influence of beta(2) adrenoceptor polymorphism. Thorax . 2000; 55 762-767
65 Lipworth B J, Hall I P, Tan S, Aziz I, Coutie W. Effects of genetic polymorphism on ex vivo and in vivo function of beta2-adrenoceptors in asthmatic patients. Chest . 1999; 115 324-328
66 Hall I P, Wheatly A, Wielding P, Light S B. Association of the Glu 27 β₂-adrenoceptor polymorphism with lower airway reactivity in asthmatic subjects. Lancet . 1995; 345 1213-1214
67 Hopes E, McDougall C, Christie G. Association of glutamine 27 polymorphism of β2 adrenoceptor with reported childhood asthma: population based study. BMJ . 1998; 316 664